Dare Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. (DARE) on June 21, 2024, with the earliest event reported on that date. The filing primarily addresses a material modification to the rights of security holders through a reverse stock split and a correction to a prior charter amendment.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-12 reverse stock split. This will reduce the number of issued and outstanding shares from approximately 101.1 million to approximately 8.4 million.
- Effective Date: The split is scheduled to become effective at 12:01 a.m. Eastern Time on July 1, 2024. Trading on a split-adjusted basis is expected to begin on July 1, 2024, on the Nasdaq Capital Market under the symbol "DARE" with a new CUSIP number (23666P200).
- Fractional Shares: No fractional shares will be issued; fractional interests will be rounded up to the next whole share.
- Adjustments: Proportionate adjustments will be made to the exercise prices and share counts for outstanding stock options, warrants, and shares available under stock incentive plans.
- Charter Correction: The Company filed a certificate of correction to fix an inadvertent omission in a 2022 amendment regarding the increase of authorized shares from 120 million to 240 million.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard implications of a reverse stock split. The primary purpose is to inform investors of the structural change to the Company's capitalization.
Investor Verification Checklist
- Verify the new CUSIP number (23666P200) for the Common Stock.
- Confirm the effective date of the reverse stock split (July 1, 2024) and the start of split-adjusted trading.
- Review the impact of the 1-for-12 ratio on the number of shares held and the per-share exercise price of any outstanding options or warrants.
- Check the treatment of fractional shares (rounded up to the next whole share).
- Confirm that the Company's percentage ownership and voting power remain unchanged, barring immaterial rounding differences.